Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of
metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic
renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine
in metastatic renal cell carcinoma patients.